The United States was once a leader in medical technology. However, increases in bureaucracy have pulled back that lead. Many new and experimental medial treatments remain illegal in the United States, which has created a significant medical tourism industry. Every year numerous Americans travel to foreign lands to seek treatment for their ailments. The latest example of this is opioid addicts traveling to Mexico to seek treatment:
As America’s opioid and heroin crisis rages, some struggling with addiction are turning to a drug illegal in the US. Jonathan Levinson went to one clinic offering the treatment in Mexico.
At the end of a dead end street in a town near the US-Mexico border, Emily Albert is in the basement of a drug treatment clinic, hallucinating about her son as a heroin addict. She imagines him going through rehab and desperately trying to get clean.
But Albert is the one with the addiction. She’s in the middle of a psychedelic treatment for opioid addiction.
The drug is illegal in the US, but several studies have suggested it is effective in alleviating opioid withdrawals and curbing addiction.
Ibogaine, along with other hallucinogenics, such as LSD and psilocybin (magic mushrooms), are schedule I substances in the US – drugs which have no medical application and are not safe for use, even under medical supervision.
The medical potential of psychedelics has been known for decades. Timothy Leary performed research on their psychological benefits in the ’50’s and ’60’s. His research discovered that psychedelics did have a lot of positive aspects. Modern research has shown that psychedelics offer a lot of potential for people suffering from depression. And now clinics in Mexico are using psychedelics to help people kick their opioid addiction.
But even with all of this information at hand, the United States government continues to claim that psychedelics have no medial application whatsoever. So long as they maintain that attitude, it is mostly illegal to experiment with psychedelics for medical purposes in the United States, which creates an impasse. A researcher can’t experiment with psychedelics to determine if they can be used in medical applications so they continue to have no medial applications, which prevents researchers from determining if they can have medical applications.
Because of this impasse, the only way to gain access to psychedelics for medical use is to travel to a country less burdened by such regulations.